Certara (NASDAQ:CERT) Upgraded to Buy at Wall Street Zen

Certara (NASDAQ:CERT) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Monday.

A number of other research firms have also weighed in on CERT. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research note on Wednesday. Craig Hallum started coverage on Certara in a report on Monday, September 29th. They set a “buy” rating and a $16.00 price target on the stock. BMO Capital Markets initiated coverage on Certara in a research report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. Zacks Research raised Certara from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Finally, KeyCorp lifted their target price on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.82.

Certara Stock Up 7.6%

Shares of CERT opened at $8.64 on Monday. Certara has a 1 year low of $8.02 and a 1 year high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The stock has a 50 day simple moving average of $11.30 and a two-hundred day simple moving average of $11.13. The firm has a market cap of $1.38 billion, a P/E ratio of 123.43 and a beta of 1.44.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period last year, the firm posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the sale, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.33% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Private Advisor Group LLC raised its holdings in Certara by 4.0% in the first quarter. Private Advisor Group LLC now owns 24,517 shares of the company’s stock worth $243,000 after buying an additional 949 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new stake in shares of Certara during the first quarter valued at $129,000. Choreo LLC boosted its position in shares of Certara by 4.1% during the first quarter. Choreo LLC now owns 52,644 shares of the company’s stock valued at $521,000 after buying an additional 2,062 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Certara in the 1st quarter worth about $2,337,000. Finally, KLP Kapitalforvaltning AS grew its stake in shares of Certara by 21.2% in the first quarter. KLP Kapitalforvaltning AS now owns 31,400 shares of the company’s stock worth $311,000 after acquiring an additional 5,500 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.